MedTrace Logo

Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)

NCT05178173 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

Randomized, double-blind prospective trial to test the efficacy of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old. All mouthrinses are commercially available and will be used according to on-label instructions. Patients will be randomized to a mouthrinse and will be asked to give a saliva sample immediately before and after a one minute mouthwash. Saliva samples will be collected from patients at 15 minute intervals thereafter up to an hour (15, 30, 45 and 60 minutes). The samples will be stored and used for real-time reverse transcription polymerase chain reaction (RT-PCR) detection of viral SARS-CoV-2 RNA and viral infectivity assays. Patients will also complete a short-survey on the taste and experience of using the mouthwash. This study involves 150 subject participants and one, 75-90 minute visit.

Conditions

  • COVID-19
  • Coronavirus Infection
  • SARS CoV 2 Infection

Interventions

OTHER

Placebo Comparator: Sterile Water

Sterile Water Placebo Comparator

OTHER

27% Ethanol plus essential oils

Over-the-counter antiseptic mouth rinse

OTHER

0.075% Cetylpyridinium Chloride

Over-the-counter antiseptic mouth rinse

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Laura A Jacox, DMD, PhD · University of North Carolina Adams School of Dentistry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2023-07-12
Completion
2023-07-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05178173 on ClinicalTrials.gov